linjc16/ctgov huggingface dataset:
The Natural History of Chronic Pancreatitis

Study Overview
=================
Brief Summary
-----------------
Chronic pancreatitis (CP) is a disease characterized by inflammation and their replacement by fibrotic tissue. The destruction of pancreatic function and structure are the main complications. This retrospective-prospective, multicenter, cohort study was conducted. This study aimed to observe the natural history of CP in China, analyse the risk factors for CP complications, and establish individual predictions.

Detailed Description
-----------------
In order to track changes consistently throughout the course of CP and facilitate the evaluation and study of CP, a dedicated database, CP Database (version number 2.1, YINMA Information Technology Inc., Shanghai, China), was established to collect clinical data of CP patients who were admitted to our centers. Data befor CP Database established were retrospectively collected according to the electronic medical record system and complemented through telephone, letter, and e-mail inquiries. Data were prospectively collected since CP Database was established. The following information was documented in detail: demographic data (age, sex, birthplace, et al), course of CP, medical history, history of other diseases, smoking and alcohol history, family history of pancreatic diseases and diabetes mellitus (DM), laboratory and imaging findings, and treatment strategy.

Official Title
-----------------
The Natural History of Chronic Pancreatitis: A Multicenter Study

Conditions
-----------------
Chronic Pancreatitis, Complication, Risk Factors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with chronic pancreatitis according to Asia-Pacific consensus Exclusion Criteria: Pancreatic cancer diagnosed within 2 years after the diagnosis of chronic pancreatitis Groove pancreatitis Autoimmune pancreatitis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pancreatic cancer | Pancreatic cancer developed in chronic pancreatitis patients | Dec 31, 2017 | 
| Diabetes mellitus | Endocrine insufficiency developed in chronic pancreatitis patients | Dec 31, 2017 | 
| Steatorrhea | Exocrine insufficiency developed in chronic pancreatitis patients | Dec 31, 2017 | 
| Pancreatic pseudocyst | Pancreatic pseudocyst developed in chronic pancreatitis patients | Dec 31, 2017 | 
| Common bile duct stricture | Common bile duct stricture developed in chronic pancreatitis patients | Dec 31, 2017 |
The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate performances of each parameters of spectral domain (Cirrus) optical coherence tomography for distinguishing between normal eyes, glaucoma suspect and glaucomatous eyes

Detailed Description
-----------------
Aim to determine which parameter of cirrus OCT is best sensitivity and specificity for glaucoma detection

Official Title
-----------------
The Performances of Spectral Domain Optical Coherence Tomography for Distinguishing Between Normal Eyes, Glaucoma Suspect and Glaucomatous Eyes

Conditions
-----------------
Glaucoma Patient, Glaucoma Suspect Patient, Normal Population, RNFL Thickness by Location, Macular Thickness by Location

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BCVA at least 20/60 refractive error +/- 5 D Or astig +/- 3 D enrolled in 3 population group (glaucoma, glaucoma suspect or normal) Exclusion Criteria: VA less than 20/60 marked RF error previous ocular trauma or surgery unreliable visual field poor signal cirrus OCT (less than 7) other causes of optic nerve or macular disease other than glaucoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glaucoma patients<br> | |
| Glaucoma suspect group<br> | |
| Normal population<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OCT, spectral domain cirrus, glaucoma, glaucoma suspect, normal population
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound

Study Overview
=================
Brief Summary
-----------------
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e. the transthoracic parametric Doppler (TPD) (EchoSense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS signals that are related to pulmonary hypertension. The TPD performance in detecting PAH in SSc patients will be assessed in the study.

Official Title
-----------------
Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)

Conditions
-----------------
Systemic Sclerosis, Pulmonary Hypertension

Intervention / Treatment
-----------------
* Radiation: Doppler ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able and willing to give signed informed consent prior to enrollment Male or female, ≥ 18 years of age Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score ≥ 9. Patients with RHC data available from measurement within 3 weeks prior to TPD assessment No change in or initiation of PAH specific therapy between the last RHC and TPD Exclusion Criteria: People unable or unwilling to give informed consent. PCWP or LVEDP > 15 mmHg Any PH etiology outside Group 1 (Dana Point, 2008) Pregnant women Patients having severe chest wall deformity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Doppler ultrasound<br>Recording Doppler signals from the lungs | Radiation: Doppler ultrasound<br>* Detecting Doppler signals from the lungs on the right chest wall<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC. | Analyze Doppler data of 4 SSc groups(according to pulmonary hypertension sevirity ) resulting in typical features. The features will be implemented in a pre-determined diagnostic algorithm that will determine the overall statistical analysis success of the method in comparison to RHC data. | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Systemic sclerosis, pulmonary hypertension
Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis

Study Overview
=================
Brief Summary
-----------------
Each patient is preoperatively treated once profylactic with intraveneous antibiotics. Postoperatively, one group will be treated with intraveneous antibiotics during 5 days. The other group will receive no antibiotics.

Official Title
-----------------
Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis

Conditions
-----------------
Uncomplicated Acute Cholecystitis

Intervention / Treatment
-----------------
* Drug: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Uncomplicated acute cholecystitis < 5 days(confirmed by echography and blood sample) > 18 years old Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: postoperatively antibiotics<br> | Drug: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis<br>* Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative complications (abces, infection of the wound) |  | day 2, day of discharge and dag 21 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of hospitalisation |  | Day O to day of discharge |
Observational Study on the Course of Plasma Glutamine Levels During Critical Illness

Study Overview
=================
Brief Summary
-----------------
Blood sampled for standard evaluation will be used for determination of plasma glutamine by Bioprofile Flex Glutamine Sensor at ICU admission

Detailed Description
-----------------
All patients who are admitted to the ICU after elective surgery and non-elective admissions. In both groups a total of 80 patients will be included. (In the trials we mentioned in the introduction 80, 174 and 66 patients were included. In the study performed by Oudemans-van Straaten a decent distribution between lower and higher levels of glutamine was achieved in 80 non-elective patients.) Exclusion criteria are patients younger then 18 years and patients who need total parenteral nutrition (TPN). The patients will receive standard care during their treatment on the ICU. Blood sampled for standard evaluation will be used for determination of plasma glutamine by Bioprofile Flex Glutamine Sensor at ICU admission. Hereafter plasma glutamine will be measured daily, a plasma sample will be taken from a standard evaluation blood sample at 6.00 am during admission on the ICU.

Official Title
-----------------
Observational Study on the Course of Plasma Glutamine Levels During Critial Illness

Conditions
-----------------
Glutamine Levels

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients admitted to the ICU Exclusion Criteria: younger then 18 years and patients who need total parenteral nutrition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glutamine in serum | glutamine level at admission and during ICU stay daily | from admission up to 8 days |
Analysis of Current Situation and Evaluation of Trauma Treatment Training in China

Study Overview
=================
Brief Summary
-----------------
This study will rely on the training course of CTCT project to conduct standardized training for trauma practitioners in China. And the quality of training will be stratified research; Continuously improve the quality of trauma treatment and improve the prognosis of trauma patients.

Official Title
-----------------
Analysis of Current Situation and Evaluation of Trauma Treatment Training in China

Conditions
-----------------
Train Accident Involving Explosion, Passenger Injured, Train Collision With Streetcar, Pedestrian Injured, Trauma Injury, Train Accident Involving Burning, Passenger Injured

Intervention / Treatment
-----------------
* Behavioral: standard trauma care taining


Participation Criteria
=================
Eligibility Criteria
-----------------
All CTCT participants from different administrative districts of China registered for standardized and procedural CTCT curriculum . All trainees have finished the general survey of personal background, trauma care status in local hospitals and pre-training tests of trauma knowledge. After CTCT curriculum and hifidelity trauma simulation training, they were also needed to finish post-training test about the initial evaluation of various kinds of traumas. The pre- and post-training examination were constantly about trauma evaluation of major trauma patients. Inclusion criteria: Trainees who attended on CTCT curriculum. Exclusion criteria: Rejection for supplying training information, in-completed CTCT training information, lack of pre- and/or post-training scores.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: post-training scores<br>evaluating qualities of trauma care after standard trauma traning | Behavioral: standard trauma care taining<br>* trauma care training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| training scores | Commare between pre- and post-training scores | Day 1.5 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| score difference | evaluation the improvement of trauma care | Day 1.5 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
trauma training, trauma care
Interferon α 2b Pharmacovigilance Study

Study Overview
=================
Brief Summary
-----------------
Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3 patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks, and the verification of sustained virological response at week 48. The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf

Official Title
-----------------
Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro)

Conditions
-----------------
Hepatitis C, Chronic

Intervention / Treatment
-----------------
* Drug: interferon α 2b + ribavirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Genotype 2/3 Chronic Hepatitis C confirmed by biomolecular technology (RNAVHC); Treatment naive; Signing the Informed Consent Form; Eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf Exclusion Criteria: Serious adverse events; Intolerance to treatment; Lost to follow up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: interferon α 2b + ribavirin|interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events | Diary for recording adverse events by patients daily; Monthly follow-up interview with MD and PharmD | Up to 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sustained virological response |  | 24 weeks after finishing treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis C, Chronic, Genotype 2/3, Interferon α 2b, Ribavirin, Pharmacovigilance
Protection Against Benzene Toxicity

Study Overview
=================
Brief Summary
-----------------
We are investigating the role of an enzyme (NQO1) in protection against the bone marrow toxicity of the occupational and environmental toxicant benzene. All of the proposed studies involve use of human bone marrow cells in-vitro to define mechanisms of NQO1-mediated protection. Cells are obtained from healthy volunteers and protocols have undergone IRB review and approval.

Official Title
-----------------
NQO1 in Protection Against Benzene Toxicity

Conditions
-----------------
Leukemia, Aplastic Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Healthy adult volunteers with blood counts in normal ranges and without evidence of hepatitis or HIV infection.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Leukemia, NQO1, DT-diaphorase, Benzene, Aplastic anemia
Prospective Cohort of Respiratory Insufficiency Outcome

Study Overview
=================
Brief Summary
-----------------
The Respiratory Insufficiency Outcome (RIO) project consists in a french multicenter prospective cohort of patients with chronic obstructive pulmonary disease (COPD) undergoing domiciliary noninvasive positive pressure ventilation.

Official Title
-----------------
Prospective Cohort of Patients With Chronic Obstructive Pulmonary Disease (COPD) Undergoing Domiciliary Noninvasive Positive Pressure Ventilation

Conditions
-----------------
COPD, Non Invasive Ventilation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of COPD domiciliary noninvasive ventilation Exclusion Criteria: noninvasive ventilation set up for a neuromuscular disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization

Study Overview
=================
Brief Summary
-----------------
A prospective pilot study to evaluate the recanalization and safety of mechanical thrombectomy through a cerebral angiogram in patients with stroke symptoms last seen normal between 8 - 24 hours.

Detailed Description
-----------------
Ischemic stroke patients who are 8-24 hrs from symptom onset without prior mechanical or IV thrombolytic treatment and are screen with CT or MR perfusion imaging showing penumbra and infarction not > 1/3rd the territory.

Official Title
-----------------
ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization

Conditions
-----------------
Ischemic Stroke

Intervention / Treatment
-----------------
* Device: mechanical thrombectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years last seen normal between 8 - 24 hours, without prior history of intravenous plasminogen activator (IV t-PA ) or mechanical thrombectomy Vessels - intracranial vertebral artery, basilar artery, intracranial ICA, ICA terminus bifurcation, MCA M1/M2, or ACA NIHSS ≥ 7 MRI DWI/PWI or CTA/P, which demonstrates an area of mismatch ≥ 2/3 rd Signed informed consent Exclusion Criteria: creat >= 2 NIHSS < 7 Baseline mRS >= 2 infarct > 1/3rd MCA territory competing trials prior IV or IA treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: with control group
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Interventional mechanical thrombectomy<br>Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours | Device: mechanical thrombectomy<br>* Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device<br>* Other names: Solitaire;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombolysis in Cerebral Infarction (TICI) score |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| National Institutes of Health Stroke Scale (NIHSS) score |  | 6 months | 
| Montreal Cognitive Assessment (MoCA) tool |  | 6 months | 
| Modified Rankin Scale |  | 6 months |